ClinicalTrials.gg
Status unknownNCT03252353OPTIMALUpdated Nov 23, 2020Results posted

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

A Phase 3 interventional study of octreotide capsules and Matching placebo in Acromegaly, sponsored by Chiasma, Inc.. Status unknown at 60 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by Chiasma, Inc. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
13th of 25
56 · median 56
Started
2017
the only one that year
Phase 3
12 of 25
1 open now
Registered
21st of 25
by date
Lead sponsor
3 of 25
Chiasma, Inc.

Among the 25 studies testing octreotide in Acromegaly, this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 12 in phase 3, and was the 21st registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to 13 months in the majority of patients with acromegaly previously managed with somatostatin analog injections (reference below).

Read the detailed description

This is a double blind, randomized study that assesses the efficacy and safety of octreotide capsules vs. placebo. Eligible acromegaly patients, treated with injectable somatostatin analogs, who are biochemically controlled and have prior evidence of active disease, will be randomized to receive either octreotide capsules or placebo for up to 36 weeks. At the end of this double blind, placebo controlled period, eligible patients will receive octreotide capsules in an open-labeled extension for at least one year. Patients failing to respond (per protocol), to oral treatment, (either placebo or octreotide capsules), will be rescued with the standard of care and upon meeting the eligibility criteria could also enroll into the long term extension with octreotide capsules.

This study received agreement from the FDA, under a special protocol assessment.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Octreotide Capsules, Acromegaly, OPTIMAL, MYCAPSSA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented evidence of active acromegaly
  • Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months with a stable dose for at least the last three months of therapy
  • Biochemically controlled

Exclusion criteria

Exclusion Criteria:

  • Patients taking injections of long-acting Somatostatin Receptor Ligands (SRLs) not as indicated in the label
  • Pituitary surgery within six months
  • Conventional or stereotactic pituitary radiotherapy any time in the past
  • Patients who previously participated in CH-ACM-01 or OOC-ACM-302
  • Any uncontrolled concomitant disease
  • Symptomatic cholelithiasis
  • Pegvisomant, within 24 weeks
  • Dopamine agonists, within 12 weeks
  • Pasireotide, within 24 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    Octreotide capsules

    Octreotide capsules

    Drug: octreotide capsules

  • Placebo comparator
    Matching Placebo

    Matching placebo capsules

    Drug: Matching placebo

Interventions

  • octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)

    Also known as: MYCAPSSA

  • DrugMatching placebo

    Matching placebo capsules

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period.

    Maintenance of response was defined by using the average IGF-1 level of the last 2 available assessments in the DPC period. If the average IGF-1 is ≤ 1×ULN, a patient was classified as a responder (i.e., maintained their biochemical response). If the average IGF-1 is \> 1×ULN, a patient was classified as a non-responder. Patients who discontinue study medication during the DPC period for any reason was classified as non-responders for the primary analysis, regardless of their IGF-1 values.

    Time frame: Week 36

Secondary outcomes

  1. Number of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period

    Maintenance of GH response was defined as having mean Growth Hormone (5 measurements 30 minutes apart) \< 2.5 ng/mL at the end of the double blind placebo controlled period, out of those who were responders on Somatostatin Receptor Ligands (SRLs) injections at Screening.

    Time frame: Week 36

  2. Number of Patients Who Begin Rescue Treatment

    Number of Patients who Began Rescue Treatment Prior to and Including Week 36

    Time frame: Week 36

07

Results

Posted Oct 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneOctreotide CapsulesMatching Placebo
Started2828
Completed2828
Not completed00

Outcome measures

PrimaryNumber of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period.

Maintenance of response was defined by using the average IGF-1 level of the last 2 available assessments in the DPC period. If the average IGF-1 is ≤ 1×ULN, a patient was classified as a responder (i.e., maintained their biochemical response). If the average IGF-1 is \> 1×ULN, a patient was classified as a non-responder. Patients who discontinue study medication during the DPC period for any reason was classified as non-responders for the primary analysis, regardless of their IGF-1 values.

Time frame:
Week 36
Reported as:
Count of participants · Participants
Number of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period.
ParticipantsOctreotide CapsulesMatching Placebo
Number of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period.165
Statistical analysis
  • Octreotide Capsules vs Matching Placebo · Regression, Logistic · p = 0.0079The adjusted proportion of responders is 58.16 for Octreotide Capsule Treatment Group vs. 19.42 for the Placebo
SecondaryNumber of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period

Maintenance of GH response was defined as having mean Growth Hormone (5 measurements 30 minutes apart) \< 2.5 ng/mL at the end of the double blind placebo controlled period, out of those who were responders on Somatostatin Receptor Ligands (SRLs) injections at Screening.

Time frame:
Week 36
Reported as:
Count of participants · Participants
Number of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period
ParticipantsOctreotide CapsulesPlacebo
Number of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period217
Statistical analysis
  • Octreotide Capsules vs Placebo · Regression, Logistic · p = 0.0007The adjusted proportion of responders is 77.66 for Octreotide Capsule Treatment Group vs. 30.40 for the Placebo
SecondaryNumber of Patients Who Begin Rescue Treatment

Number of Patients who Began Rescue Treatment Prior to and Including Week 36

Time frame:
Week 36
Reported as:
Count of participants · Participants
Number of Patients Who Begin Rescue Treatment
ParticipantsOctreotide CapsulesPlacebo
Number of Patients Who Begin Rescue Treatment719
Statistical analysis
  • Octreotide Capsules vs Placebo · Fisher Exact · p = 0.0029

Adverse events

Collected over 1 year, 10 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide Capsules0/28 (0%)2/28 (7.1%)28/28 (100%)
Matching Placebo0/28 (0%)1/28 (3.6%)27/28 (96.4%)
Most frequent serious events
Most frequent serious events
EventOctreotide CapsulesMatching Placebo
Cholecystitis acuteHepatobiliary disorders1/280/28
Joint dislocationInjury, poisoning and procedural complications0/281/28
ArthritisMusculoskeletal and connective tissue disorders1/280/28
Most frequent other events
Showing 10 of 40
Most frequent other events
EventOctreotide CapsulesMatching Placebo
ArthralgiaMusculoskeletal and connective tissue disorders9/2816/28
HeadacheNervous system disorders4/289/28
DiarrhoeaGastrointestinal disorders8/286/28
FatigueGeneral disorders2/287/28
HyperhidrosisSkin and subcutaneous tissue disorders6/287/28
NauseaGastrointestinal disorders6/283/28
Abdominal discomfortGastrointestinal disorders4/283/28
ConstipationGastrointestinal disorders3/284/28
VomitingGastrointestinal disorders4/280/28
Peripheral swellingGeneral disorders3/284/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Octreotide CapsulesMatching PlaceboTotal
Age55.3 ± 11.9754.2 ± 10.9654.7 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)Octreotide CapsulesMatching PlaceboTotal
Female161430
Male121426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Octreotide CapsulesMatching PlaceboTotal
Hispanic or Latino033
Not Hispanic or Latino282553
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Octreotide CapsulesMatching PlaceboTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American011
White272451
More than one race000
Unknown or Not Reported011
Baseline average Insulin-like Growth Factor 1 (IGF-1) (categorical)
Baseline average Insulin-like Growth Factor 1 (IGF-1) (categorical)(Participants)Octreotide CapsulesMatching PlaceboTotal
IGF≤ 1 Upper Limit of Normal (ULN)272350
IGF > 1 to < 1.3 ULN156
IGF≥ 1.3 ULN000
08

Study locations

60 sites
  • Keck Medical Center of University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • John H. Stroger Jr. Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Johns Hopkins University Clinical Trials Unit
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43203, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny Endocrinology Associates
    Pittsburgh, Pennsylvania 15212, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Huntsman Cancer Hospital
    Salt Lake City, Utah 84108, United States
  • St Vincent's Private Hospital-NSW
    Darlinghurst, New South Wales 2010, Australia
  • Royal North Shore Public Hospital
    St Leonards, New South Wales 2065, Australia
  • St Vincent's Hospital-VIC
    Fitzroy, Victoria 3065, Australia
  • The Alfred
    Melbourne, Victoria 3004, Australia
  • Melbourne Health
    Parkville, Victoria 3050, Australia
  • Keogh Institute (Sir Charles Gardner)
    Nedlands, Western Australia 6009, Australia
  • University Specialized Hospital for Active Treatment of Endocrinology "Acad. Iv. Pencev" EAD
    Sofia, 1431, Bulgaria
  • University of British Columbia
    Vancouver, British Columbia V5Z 1M9, Canada
  • St Joseph's Health Care
    London, Ontario N6A 4V2, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Aarhus University Hospital
    Aarhus, 8000, Denmark
  • Rigshospitalet The Department of Endocrinology
    Copenhagen, 2100, Denmark
  • RWTH Aachen University Hospital, Medical Clinic III Division of Endocrinology and Diabetes
    Aachen, 52074, Germany
  • Klinikum der LMU Muenchen, Medizinische Klinik und Poliklinik IV, Endokrinologie
    Munich, 80336, Germany
  • Magyar Honvedseg Egeszsegugyi Kozpont, II. sz. Belgyogyaszati Osztaly
    Budapest, H-1062, Hungary
  • University of Semmelweiss, Budapest
    Budapest, H-1088, Hungary
  • Szegedi Tudományegyetem, I. Belgyógyászati Klinika
    Szeged, H-6720, Hungary
  • Hadassah Ein-Karem Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center, Beilinson Hospital
    Petah Tikva, 49100, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia
    Monserrato, 09042, Italy
  • Azienda Ospedaliero-Universitaria Pisana, Università di Pisa
    Pisa, 56124, Italy
  • Riga Eastern Clinical University, Hospital Gailezers Department of Endocrinology
    Riga, 1038, Latvia
  • Leids Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CE, Netherlands
  • Dunedin Hospital
    Dunedin, 9016, New Zealand
  • Wellington Hospital
    Wellington, 6021, New Zealand
  • Katedra i Klinika Endokrynologii i Chorob Wewnetrznych
    Gdansk, 80-211, Poland
  • Uniwersyteckie Centrum Okulistyki i Onkologii Samodzielny Publiczny Szpital Kliniczny Slaskiego Uniwersytetu Medycznego w Katowicach, Oddzial Endokrynologii
    Katowice, 40-541, Poland
  • Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Endokrynologii
    Krakow, 31-501, Poland
  • Klinika Chorob Wewnetrznych i Endokrynologii
    Warszawa, 02-097, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
    Wroclaw, 50-367, Poland
  • Medical University Centre Ljubljana
    Ljubljana, 1000, Slovenia
  • Sahlgrenska University Hospital
    Göteborg, SE-413 45, Sweden
  • Ankara University, Faculty of Medicine
    Ankara, 6100, Turkey
  • Hacettepe University Medical School
    Ankara, 6100, Turkey
  • Ege University Medical Faculty Internal Diseases
    İzmir, 35040, Turkey
  • Erciyes University Medical Faculty
    Kayseri, 38080, Turkey
  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
  • Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9. Erratum In: J Clin Endocrinol Metab. 2016 Oct;101(10):3863. doi: 10.1210/jc.2016-4113. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa637. doi: 10.1210/clinem/dgaa637. PubMed 25664604 ↗
  • Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012 Jul;97(7):2362-9. doi: 10.1210/jc.2012-1179. Epub 2012 Apr 26. PubMed 22539587 ↗
  • Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. 2021 Dec;24(6):943-953. doi: 10.1007/s11102-021-01163-2. Epub 2021 Jun 25. Erratum In: Pituitary. 2021 Dec;24(6):954. doi: 10.1007/s11102-021-01177-w. PubMed 34173129 ↗
  • Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3785-97. doi: 10.1210/clinem/dgaa526. PubMed 32882036 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Jun 2019, 21 months.

Results were first posted in Oct 2020, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2017
First posted
Aug 17, 2017
StartActual
Sep 1, 2017
Primary completionActual
Jun 13, 2019
CompletionEst.
May 2022
Results first posted
Oct 19, 2020
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03252353
Lead sponsor
Chiasma, Inc.
Responsible party
Sponsor
First posted
Aug 17, 2017
Start date
Sep 1, 2017
Primary completion
Jun 13, 2019
Completion
May 2022 (estimated)
Results posted
Oct 19, 2020
Last update
Nov 23, 2020

Study contacts

Susan L Samson, MD PhD
study chair · Pituitary Center at Baylor St. Luke's Medical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion